Member area login
You don't have or don't remember the password!
Click Here
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282


ISSN print: 0393 – 0564
ISSN digital: 0392- 7091

BC: Articoli scritti da F. Pane

Valutazione molecolare nella leucemia mieloide cronica
Molecular monitoring in chronic myeloid leukemia (CML)
<p>The pathognomonic genetic alteration in CML is the&nbsp;formation of the BCR-ABL fusion gene, which produces a constitutively active tyrosine kinase that drives leukemic&nbsp;transformation. Targeted tyrosine kinase inhibitor treatment is the cornerstone of modern therapy for this hematologic&nbsp;malignancy. Analysis of BCR-ABL [through reverse transcriptase-quantitative polymerase chain reaction (RT-QPCR)]&nbsp;is the gold standard approach for quantitatively assessing minimal residual disease and monitoring the efficacy of&nbsp;tyrosine kinase inhibitor therapy in CML patients. The continuous therapeutic improvement has led to increasingly&nbsp;ambitious treatment endpoints, which, in turn, require more and more refined measurement and definition of&nbsp;molecular response levels. For these reasons standardization efforts of monitoring by RT-QPCR are now focused on&nbsp;ensuring reliable and harmonized expression of quantitative results.</p>
Biochimica Clinica ; 39(2) 094-099
Rassegne - Reviews
Identificazione e ruolo dell’esperto in emostasi e trombosi nel Sistema Sanitario Nazionale
Identification and role of the hemostasis and thrombosis expert in the National Health System
<p>Hemorrhagic&nbsp;and thrombotic diseases are very heterogeneous disorders that may affect a relevant part of the population, as in the&nbsp;case of patients taking antithrombotic drugs. The appropriate management of such conditions requires the availability&nbsp;of specific laboratory assays, together with the knowledge of possible clinical syndromes and of their appropriate&nbsp;treatments. This can be achieved only through second level specialized laboratories supervised by trained personnel.&nbsp;This type of diagnostic and therapeutic organization is not widely available in Italy, but it is present in a limited number&nbsp;of major hospitals, having a nationwide excellence. Increasing the availability of such resources would be very&nbsp;relevant for patients and this effort could also be cost-effective for the National Health System. This document,&nbsp;promoted by the Societ&agrave; Italiana per lo Studio dell&rsquo;Emostasi e della Trombosi and by other major national scientific&nbsp;societies involved in the field is aimed at identifying the level of scientific and professional career required to define&nbsp;a physician as hemostasis and thrombosis expert, graded for the skills required in different clinical settings.</p>
Biochimica Clinica ; 38(1) 39-46
Documenti SIBioC - SIBioC Documents